|
Status |
Public on Dec 07, 2020 |
Title |
AB01_AB1_Day0_RS |
Sample type |
SRA |
|
|
Source name |
AB1 tumour
|
Organism |
Mus musculus |
Characteristics |
tissue: AB1 tumour age: 8-10 weeks gender: f treatment: aCTLA-4 + aPDL1 group: RS strain: balb/c timepoint: d0
|
Treatment protocol |
100ug anti-CTLA-4 + anti-PDL1 given i.p., follwed by 100ug anti-PDL1 i.p. given 2 and 4 days later *Note some samples were collected before treatment
|
Growth protocol |
Subcutaneous tumour growth
|
Extracted molecule |
total RNA |
Extraction protocol |
Frozen tumour dissociation with Trizol followed by chloroform extraction and purification using RNeasy MinElute Illumina 50bp single-end sequencing
|
|
|
Library strategy |
RNA-Seq |
Library source |
transcriptomic |
Library selection |
cDNA |
Instrument model |
Illumina HiSeq 2000 |
|
|
Description |
AB01
|
Data processing |
read alignment with Kallisto count quantification with tximport Genome_build: GRCm38.p6 Supplementary_files_format_and_content: txt files in compressed gz format
|
|
|
Submission date |
Jul 07, 2020 |
Last update date |
Dec 07, 2020 |
Contact name |
Wee Loong Chin |
Organization name |
National Centre For Asbestos Related Diseases
|
Street address |
Level 5, Qq Block, Qeii Medical Centre 6 Verdun St, Nedlands
|
City |
Perth |
ZIP/Postal code |
6009 |
Country |
Australia |
|
|
Platform ID |
GPL13112 |
Series (2) |
GSE153941 |
Dynamic IFNβ signalling underlies treatment response to immune checkpoint therapy in cancer [bulk RNA-seq] |
GSE153943 |
Dynamic IFNβ signalling underlies treatment response to immune checkpoint therapy in cancer |
|
Relations |
Alternative to |
GSM3291713 |
BioSample |
SAMN15464555 |
SRA |
SRX8679966 |